Argus Research analyst John Staszak downgrades Nike (NYSE:NKE) from Buy to Hold.
AstraZeneca Axes Pneumonia Drug Pact With Aridis
AstraZeneca plc (NASDAQ: AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS).
Argus Research Downgrades Nike to Hold
Argus Research analyst John Staszak downgrades Nike (NYSE:NKE) from Buy to Hold.
Related Posts
Hour Loop Q3 EPS $(0.0004) Up From $0.01 YoY, Sales $29.15M Up From $17.56M YoY
Third Quarter 2023 Financial ResultsNet revenues in the third quarter of 2023 were $29.2 million, compared to $17.6 million in the year-ago period. The increase was primarily due to continued growth and maturity in our
Elon Musk’s Favorite Crypto To Hit $1 Next Year? Analyst Says ‘Now Is The Time’ To Enter ‘For The Long Term’
Pseudonymous crypto analyst, Captain Faibik, believes that Dogecoin (CRYPTO: DOGE) — Tesla CEO Elon Musk‘s
Charles Gasparino Tweets “PE Powerhouse Blackstone Has Secured Financing For $6B Renewable Energy Project In NYS, One Of The Largest Of Its Kind; Blackstone To Announce Financing Terms Imminently; PE Firm Will Take $1B Equity Stake In The Project Plus…
https://twitter.com/CGasparino/status/1572310392725987329